Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.

Loading...
Thumbnail Image

Date

2008-07

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

263
views
500
downloads

Citation Stats

Abstract

Chemoprevention agents are an emerging new scientific area that holds out the promise of delaying or avoiding a number of common cancers. These new agents face significant scientific, regulatory, and economic barriers, however, which have limited investment in their research and development (R&D). These barriers include above-average clinical trial scales, lengthy time frames between discovery and Food and Drug Administration approval, liability risks (because they are given to healthy individuals), and a growing funding gap for early-stage candidates. The longer time frames and risks associated with chemoprevention also cause exclusivity time on core patents to be limited or subject to significant uncertainties. We conclude that chemoprevention uniquely challenges the structure of incentives embodied in the economic, regulatory, and patent policies for the biopharmaceutical industry. Many of these policy issues are illustrated by the recently Food and Drug Administration-approved preventive agents Gardasil and raloxifene. Our recommendations to increase R&D investment in chemoprevention agents include (a) increased data exclusivity times on new biological and chemical drugs to compensate for longer gestation periods and increasing R&D costs; chemoprevention is at the far end of the distribution in this regard; (b) policies such as early-stage research grants and clinical development tax credits targeted specifically to chemoprevention agents (these are policies that have been very successful in increasing R&D investment for orphan drugs); and (c) a no-fault liability insurance program like that currently in place for children's vaccines.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1158/1940-6207.CAPR-08-0048

Publication Info

Moe, Jeffrey L (2008). Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention. Cancer Prev Res (Phila), 1(2). pp. 84–90. 10.1158/1940-6207.CAPR-08-0048 Retrieved from https://hdl.handle.net/10161/6433.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Moe

Jeffrey Moe

Adjunct Professor of Global Health

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.